We would love to hear your thoughts about our site and services, please take our survey here.
That’s assuming we don’t get hit by an asteroid and life as we know it ceases to exist
Anyway, Avalyn’s phase 2b funding is irrelevant to NFX at this stage as Nuformix are in talks already for outlicence / partnering and won’t be going solo like Avalyn are doing.
By comparison, Avalyn are dosing at 100 milligrams, NXP002 was dosing at 100 micrograms and getting better results.
(There are 1000 micrograms in 1 milligram)
Good luck to Avalyn but they’re asking a lot of their patients.
The size of dose they require is massive, they are basically asking people to inhale a whole tablet twice a day to get average results.
“Participants were randomized to one of two treatment arms: 50 mg AP01 once daily (QD) or 100 mg twice daily (BID) delivered with the eFlow Nebulizer System“
Interestingly from Bristol-Myers phase 2 testing of their drug for PPF Progressive Pulmonary Fibrosis (less common than IPF), they trials 38% of patients in combination with either Esbriet or Ofev as standard of care, so could see its use as an add-on.
Indirectly this backs up NFX looking at nxp002 in combination with standard of care if the big boys are also looking at the same principle.
https://www.fiercebiotech.com/biotech/second-phase-2-win-bms-builds-case-first-class-contender-pulmonary-fibrosis
Yay! well done NFT's. Good to see your working and thank you.
Only things I would comment / add.
You'll need to add a guesstimate for the NXP001 payment they received last week (rns stated they had been paid immediately), my guesstimate is between 50k-100k for the immediate payment, so lets go with the low figure.
So lets say end of Sept 2023 cash position would be £600k
Post Sept year end.
There is a new near term payment from Oxilio, plus their payment at the end of phase 1 testing. So lets say £50k + £100k (as end of phase 1 is a milestone payment and on a par with previous)
Also remember there are warrants outstanding which when exercised will net £87.5k
So theres another circa £137k pending as income.
£600k less your deductions, I'm not 100% convinced on the £350k tests as the company are seeking a partnering deal which will cover this but will run with it..
£600k deduct costs of £510k leaves £90k cash witch income due of around £130k , so £220k cash or cash equivalents.
Show your workings please, then we'll chat.
Just to go back to July again NFT's, remember I posted my workings as to the cash position.
I asked you to present your workings as you say they don't have cash, but you still can't actually come up with anything to back up your argument? Any development on that front?
Maybe once you're chilled out you will read the paper I posted last night, that will help you understand the process thats happening at the moment.
The rat studies were successful in demonatrating tolerability, they had difficulty in consistent results for duration of action only. As the Boehringer paper outlines, this is common in IPF preclinial as rats are not the best medium to test on, they just happen to be the industry standard and majors are now moving away from that due to these issue.
NFX have subsequently proven duration of action which has closed out the question mark from early last year.
This was presented by Fibrofind at the recent IPF Summit.
Such desperation... chill out NFT's.
Man who said this would crash in July now says december
Good read in this paper from Boehringer.
Covers ground as to how the IPF treatment scene is changing to combination therapies with short trial spans
https://www.frontiersin.org/articles/10.3389/fphar.2022.823085/full
Again, so worked up for someone with no interest here.
Anyway, as you’ve established. NFX submitted an amendment to the patent on July 21st, deleting claims 11 and 12 in compliance with the patent officer.
But hey, you obviously knew that.
Well done NFTs we are getting somewhere.
So, since the refusal only relates to claims 11 and 12, can you tell me what amendment to the patent NFX have submitted?
Now NFT's, lets look at what you actually copy pasted.
This is from your post.
"At present, no reasons for refusal are found with respect to the inventions according to Claims ( 1-10,13-21 ) at present at this point."
Do you understand what that means?
NFT's, has the patent been categorically rejected with no chance of appeal or amendment? No, its still in progress.
Its as simple as that.
As I said, with your research, you will know that this has happened before and the patent subsequently granted. Patent approval is a process, not a one off moon shot. Hence the company hasn't had to announce anything because its not reached a conclusion yet.
You can enter negotiations at anytime, it all depends on what the parties want.
Again, you seem very worked up about this for some reason on a Sunday night when its been known for months?
Again, nothing for you to worry about is there. You seem very worked up about it for some reason, just chill out you don't hold any stock anyway.
As you will know, this has happened before with the company appealing a patent refusal for NXP002 and then subsequently being granted. I didn't hear you squeeling about that at the time.
The company hasn't hidden anything, its been in the public domain since March when it was uploaded to the WIPO website. I talked about it months ago when you were still holding.
Thanks NFTs we've covered the patent side of things a few days ago, they've removed the clause as requested by the examiner.
Nothing for you to worry about after all you sold at what 0.24p on 17 April?
Thanks Chab and well done on making a bit here over time, also for having a 0.28p level now.
It will be what it will be.